Table 1 Clinicopathological characteristics (n = 271)
From: p53 nuclear accumulation as an early indicator of lethal prostate cancer
Characteristic | Number (% or range) |
|---|---|
Age at RP (years) | 64 (43–76) |
Length of follow-up (years) | 15 (0.3–24) |
Pre-operative PSA (ng/mL) | 11 (1–280) |
Pathological T stage | |
T2N0 | 127 (47) |
T3aN0 | 87 (27) |
T3bN0 | 45 (17) |
T4N0 | 5 (2) |
TxN+ | 6 (2) |
Updated Gleason grade (ISUP grade group) | |
≤6 (1) | 49 (20) |
3+4 (2) | 108 (45) |
4+3 (3) | 47 (12) |
8 (4) | 12 (5) |
≥9 (5) | 25 (10) |
Extraprostatic extension | 138 (51) |
Seminal vesicle invasion | 50 (18) |
Margin involvement | 140 (52) |
Adjuvant therapy | |
Radiotherapy | 12 (4) |
Androgen deprivation therapy | 39 (14) |
Radiotherapy and androgen deprivation therapy | 5 (2) |
Clinical outcome | |
Biochemical relapse | 156 (58) |
Metastatic relapse | 42 (15) |
Prostate cancer death | 25 (9) |
Death from any cause | 123 (45) |
